Trial Profile
Efficacy Of Eculizumab Therapy In Patients With Transplant-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology